Danaher Corporation (DHR) — Fair Value Analysis

Base-case fair value (P50): $173.69 · Current price: $202.45 · Verdict: Fairly Valued

The Verdict on DHR

Based on our Monte Carlo simulations, Danaher Corporation (DHR) is currently Overvalued. The analysis indicates a median fair value (P50) of $173.69, which stands significantly below the current market price of $202.45. This disparity implies a -14.2% downside, suggesting DHR trades at a premium unsupported by its fundamental valuation under a range of forward-looking scenarios. Investors should note this considerable gap when evaluating DHR's present market positioning.

How DHR stacks up against Healthcare

DHR's valuation picture is further complicated by its quality tier within the Healthcare sector. Our assessment classifies DHR's operational and financial health as "weak" relative to its sector peers. Despite this weaker quality tier, the stock is trading at $202.45, which is well above its calculated fair value of $173.69. This suggests that the market may be assigning a higher valuation to DHR than its underlying operational strength within the Healthcare sector might warrant, reflecting a potential disconnect between price and fundamental quality given the -14.2% overvaluation.

What this means for investors

For investors considering Danaher (DHR), the current analysis points to a clear overvaluation. The median fair value of $173.69 is substantially lower than the present market price of $202.45, signaling a -14.2% downside based on our simulations. This assessment, combined with DHR's "weak" quality tier within the Healthcare sector, suggests caution. To gain a deeper understanding of the potential range of outcomes, including detailed bear and bull case scenarios, sign up for a free FairCurve account. You can track DHR's fair value as new fundamentals are released.